Tags

Type your tag names separated by a space and hit enter

The effectiveness of interferon beta versus glatiramer acetate and natalizumab versus fingolimod in a Polish real-world population.
PLoS One. 2019; 14(10):e0223863.Plos

Abstract

OBJECTIVE

The aim of the study was to assess the effectiveness of disease-modifying therapies (DMTs) in relapsing-remitting multiple sclerosis (RRMS) patients treated in MS centres in Poland.

METHODS

Demographic and clinical data of all Polish RRMS patients receiving DMTs were prospectively collected from 2014 to 2018 in electronic files using the Therapeutic Program Monitoring System (SMPT).

RESULTS

The study included 10,764 RRMS patients treated with DMTs in first-line and 1,042 in second-line programmes. IFNβ more effectively lengthened the times to the first relapse, disability progression, and brain MRI activity than GA. After 2 and 4 years of follow-up, more patients on IFNβ showed no evidence of disease activity (NEDA-3) in comparison to GA (66.3% and 44.3% vs 55.2% and 33.2%, respectively; p<0.001). NAT more effectively reduced brain MRI activity than FTY (p = 0.001). More patients under NAT had NEDA-3 after 2 and 4 years of follow-up compared to FTY (66.2% and 42.1% vs 52.1% and 29.5%, respectively; p = 0.03). In adjusted analysis, a higher baseline Expanded Disability Status Score (EDSS) was a predictor of relapse (p<0.001) and NEDA-3 failure (p = 0.003).

CONCLUSION

IFNβ compared to GA and NAT compared to FTY more effectively reduced disease activity in a Polish population of RRMS patients.

Authors+Show Affiliations

Department of Neurology, Medical University of Bialystok, Bialystok, Poland.Department of Neurology, Medical University of Bialystok, Bialystok, Poland.Centre for Bioinformatics and Data Analysis, Medical University of Bialystok, Bialystok, Poland.The Faculty of Medicine and Health Sciences, Institute of Physiotherapy, Jan Kochanowski University, Kielce, Poland.Department of Neurology, Medical University of Bialystok, Bialystok, Poland.Department of Neurology, Medical University of Bialystok, Bialystok, Poland.Centre for Bioinformatics and Data Analysis, Medical University of Bialystok, Bialystok, Poland.Neurology Clinic with Brain Stroke Sub-Unit, Clinical Hospital No. 2 in Rzeszow, Medical Faculty, University of Rzeszow, Rzeszów, Poland.Department of Neurology in Zabrze, Medical University of Silesia, Zabrze, Poland.Department of Neurology, Medical University of Bialystok, Bialystok, Poland.Department of Neurology, Medical University of Bialystok, Bialystok, Poland.

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

31647829

Citation

Kapica-Topczewska, Katarzyna, et al. "The Effectiveness of Interferon Beta Versus Glatiramer Acetate and Natalizumab Versus Fingolimod in a Polish Real-world Population." PloS One, vol. 14, no. 10, 2019, pp. e0223863.
Kapica-Topczewska K, Tarasiuk J, Collin F, et al. The effectiveness of interferon beta versus glatiramer acetate and natalizumab versus fingolimod in a Polish real-world population. PLoS ONE. 2019;14(10):e0223863.
Kapica-Topczewska, K., Tarasiuk, J., Collin, F., Brola, W., Chorąży, M., Czarnowska, A., Kwaśniewski, M., Bartosik-Psujek, H., Adamczyk-Sowa, M., Kochanowicz, J., & Kułakowska, A. (2019). The effectiveness of interferon beta versus glatiramer acetate and natalizumab versus fingolimod in a Polish real-world population. PloS One, 14(10), e0223863. https://doi.org/10.1371/journal.pone.0223863
Kapica-Topczewska K, et al. The Effectiveness of Interferon Beta Versus Glatiramer Acetate and Natalizumab Versus Fingolimod in a Polish Real-world Population. PLoS ONE. 2019;14(10):e0223863. PubMed PMID: 31647829.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The effectiveness of interferon beta versus glatiramer acetate and natalizumab versus fingolimod in a Polish real-world population. AU - Kapica-Topczewska,Katarzyna, AU - Tarasiuk,Joanna, AU - Collin,Francois, AU - Brola,Waldemar, AU - Chorąży,Monika, AU - Czarnowska,Agata, AU - Kwaśniewski,Mirosław, AU - Bartosik-Psujek,Halina, AU - Adamczyk-Sowa,Monika, AU - Kochanowicz,Jan, AU - Kułakowska,Alina, Y1 - 2019/10/24/ PY - 2019/07/12/received PY - 2019/09/30/accepted PY - 2019/10/25/entrez PY - 2019/10/28/pubmed PY - 2020/3/20/medline SP - e0223863 EP - e0223863 JF - PloS one JO - PLoS ONE VL - 14 IS - 10 N2 - OBJECTIVE: The aim of the study was to assess the effectiveness of disease-modifying therapies (DMTs) in relapsing-remitting multiple sclerosis (RRMS) patients treated in MS centres in Poland. METHODS: Demographic and clinical data of all Polish RRMS patients receiving DMTs were prospectively collected from 2014 to 2018 in electronic files using the Therapeutic Program Monitoring System (SMPT). RESULTS: The study included 10,764 RRMS patients treated with DMTs in first-line and 1,042 in second-line programmes. IFNβ more effectively lengthened the times to the first relapse, disability progression, and brain MRI activity than GA. After 2 and 4 years of follow-up, more patients on IFNβ showed no evidence of disease activity (NEDA-3) in comparison to GA (66.3% and 44.3% vs 55.2% and 33.2%, respectively; p<0.001). NAT more effectively reduced brain MRI activity than FTY (p = 0.001). More patients under NAT had NEDA-3 after 2 and 4 years of follow-up compared to FTY (66.2% and 42.1% vs 52.1% and 29.5%, respectively; p = 0.03). In adjusted analysis, a higher baseline Expanded Disability Status Score (EDSS) was a predictor of relapse (p<0.001) and NEDA-3 failure (p = 0.003). CONCLUSION: IFNβ compared to GA and NAT compared to FTY more effectively reduced disease activity in a Polish population of RRMS patients. SN - 1932-6203 UR - https://www.unboundmedicine.com/medline/citation/31647829/The_effectiveness_of_interferon_beta_versus_glatiramer_acetate_and_natalizumab_versus_fingolimod_in_a_Polish_real_world_population_ L2 - http://dx.plos.org/10.1371/journal.pone.0223863 DB - PRIME DP - Unbound Medicine ER -